Amedisys’ (AMED) Hold Rating Reaffirmed at Robert W. Baird
Robert W. Baird reaffirmed their hold rating on shares of Amedisys Inc (NASDAQ:AMED) in a research report released on Wednesday. The firm currently has a $50.00 target price on the health services provider’s stock.
A number of other research analysts have also issued reports on AMED. BidaskClub lowered Amedisys from a hold rating to a sell rating in a report on Saturday, August 5th. Bank of America Corporation assumed coverage on Amedisys in a report on Monday, August 21st. They issued a neutral rating and a $55.00 target price for the company. Oppenheimer Holdings, Inc. reiterated a buy rating and issued a $60.00 target price on shares of Amedisys in a report on Friday, September 15th. Finally, Mizuho lowered Amedisys from a buy rating to a neutral rating and set a $50.00 target price for the company. in a report on Wednesday, July 26th. Seven investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Amedisys presently has an average rating of Hold and an average price target of $55.44.
Shares of Amedisys (NASDAQ AMED) traded down 0.06% during midday trading on Wednesday, hitting $53.47. The company had a trading volume of 230,414 shares. Amedisys has a 12 month low of $34.58 and a 12 month high of $65.91. The firm has a market capitalization of $1.81 billion, a PE ratio of 45.70 and a beta of 0.87. The company has a 50-day moving average of $51.90 and a 200 day moving average of $55.18.
Amedisys (NASDAQ:AMED) last released its earnings results on Wednesday, July 26th. The health services provider reported $0.62 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.50 by $0.12. The firm had revenue of $378.80 million during the quarter, compared to analyst estimates of $380.80 million. Amedisys had a return on equity of 13.71% and a net margin of 2.70%. Amedisys’s revenue was up 5.0% compared to the same quarter last year. During the same period last year, the business posted $0.42 earnings per share. On average, analysts expect that Amedisys will post $2.21 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This news story was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://www.watchlistnews.com/amedisys-amed-hold-rating-reaffirmed-at-robert-w-baird/1610957.html.
In other Amedisys news, insider David B. Pearce sold 1,000 shares of Amedisys stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $50.00, for a total transaction of $50,000.00. Following the completion of the sale, the insider now directly owns 10,488 shares of the company’s stock, valued at approximately $524,400. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bruce D. Perkins purchased 2,000 shares of the firm’s stock in a transaction on Thursday, August 3rd. The shares were acquired at an average cost of $46.60 per share, with a total value of $93,200.00. Following the completion of the acquisition, the director now directly owns 15,825 shares in the company, valued at $737,445. The disclosure for this purchase can be found here. 2.00% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in AMED. Riverhead Capital Management LLC lifted its holdings in Amedisys by 75.5% during the 2nd quarter. Riverhead Capital Management LLC now owns 1,931 shares of the health services provider’s stock worth $121,000 after buying an additional 831 shares during the last quarter. Federated Investors Inc. PA lifted its holdings in Amedisys by 2.3% during the 2nd quarter. Federated Investors Inc. PA now owns 1,929 shares of the health services provider’s stock worth $122,000 after buying an additional 44 shares during the last quarter. Ameritas Investment Partners Inc. purchased a new stake in Amedisys during the 1st quarter worth about $123,000. CIBC Asset Management Inc purchased a new stake in Amedisys during the 2nd quarter worth about $230,000. Finally, SG Americas Securities LLC lifted its holdings in Amedisys by 48.7% during the 2nd quarter. SG Americas Securities LLC now owns 3,743 shares of the health services provider’s stock worth $235,000 after buying an additional 1,226 shares during the last quarter. 96.55% of the stock is owned by institutional investors.
Amedisys Company Profile
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.